All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

desipramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
substances of the imipramine group	812	50-47-5

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: desipramine demethylimipramine desimipramine desipramin desmethylimipramine methylaminopropyliminodibenzyl monodemethylimipramine norimipramine desipramine hydrochloride desipramine HCl

A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors. Molecular weight: 266.39 Formula: C18H22N2 CLOGP: 4.47 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 15.27 ALOGS: -3.83 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	16.09 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	82.50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	15 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	11 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.16 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	22 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 20, 1964	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	146.44	31.45	67	1182	133766	56157052
Hyperkeratosis	114.52	31.45	26	1223	5321	56285497
Cardiac murmur	94.97	31.45	26	1223	11375	56279443
Angina pectoris	71.99	31.45	26	1223	27950	56262868
Immune thrombocytopenia	66.63	31.45	19	1230	9606	56281212
Dyspnoea exertional	61.39	31.45	28	1221	54661	56236157
Intestinal obstruction	50.23	31.45	20	1229	27951	56262867
Urinary retention	46.70	31.45	19	1230	28055	56262763
Ileus	43.68	31.45	15	1234	13867	56276951
Toxicity to various agents	36.62	31.45	34	1215	224530	56066288
Osteoarthritis	32.74	31.45	21	1228	80275	56210543
Therapy non-responder	32.57	31.45	19	1230	61336	56229482

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	71.71	35.76	33	483	91481	31605347

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	203.17	27.49	101	1582	227034	70699727
Hyperkeratosis	75.87	27.49	20	1663	7064	70919697
Cardiac murmur	65.14	27.49	20	1663	12166	70914595
Immune thrombocytopenia	55.46	27.49	19	1664	16305	70910456
Toxicity to various agents	48.44	27.49	52	1631	382120	70544641
Intestinal obstruction	45.70	27.49	21	1662	38804	70887957
Angina pectoris	41.30	27.49	21	1662	48362	70878399
Dyspnoea exertional	39.37	27.49	24	1659	78406	70848355
Ileus	34.56	27.49	15	1668	24222	70902539
Urinary retention	34.10	27.49	19	1664	52501	70874260
Osteoarthritis	32.94	27.49	21	1662	74126	70852635
Drug intolerance	32.59	27.49	33	1650	225654	70701107
Therapy non-responder	32.24	27.49	21	1662	76894	70849867

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AA01	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors
CHEBI has role	CHEBI:88188	allergenic drug
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018759	Adrenergic Uptake Inhibitors
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D000929	Antidepressive Agents, Tricyclic
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
FDA EPC	N0000175752	Tricyclic Antidepressant
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35640	adrenergic uptake inhibitors
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:37955	H1 receptor antagonists
CHEBI has role	CHEBI:48873	acetylcholine receptor antagonist
CHEBI has role	CHEBI:50949	SSRI
CHEBI has role	CHEBI:76779	post-proline endopeptidase inhibitors
CHEBI has role	CHEBI:76811	sphingomyelin cholinephosphohydrolase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Depressive disorder	indication	35489007
Cataplexy	off-label use	46263000
Anxiety	off-label use	48694002
Bulimia nervosa	off-label use	78004001
Neuropathic pain	off-label use	247398009
Chronic idiopathic urticaria	off-label use	302162004
Panic disorder	off-label use	371631005	DOID:594
Attention deficit hyperactivity disorder	off-label use	406506008
Depressive Disorder following Traumatic Brain Injury	off-label use
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Bipolar disorder	contraindication	13746004	DOID:3312
Lowered convulsive threshold	contraindication	19260006
Glaucoma	contraindication	23986001	DOID:1686
Torsades de pointes	contraindication	31722008
Hyperthyroidism	contraindication	34486009	DOID:7998
Conduction disorder of the heart	contraindication	44808001
Schizophrenia	contraindication	58214004	DOID:5419
Epilepsy	contraindication	84757009	DOID:1826
Kidney disease	contraindication	90708001	DOID:557
Prolonged QT interval	contraindication	111975006
Seizure disorder	contraindication	128613002
Cerebrovascular accident	contraindication	230690007
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Myocardial infarction in recovery phase	contraindication	418044006
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.83	Basic
pKa2	5.01	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Kd	9.08		WOMBAT-PK	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	5.63		PDSP
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.86		PDSP
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	5.86		WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Kd	7.76		WOMBAT-PK
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.19		PDSP
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.80		WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		EC50	6.50		WOMBAT-PK
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		EC50	6.50		WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7		WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN					WOMBAT-PK
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	7.12		WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.76		WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	6.27		WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.68		WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.80		WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.84		WOMBAT-PK
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	6.98		PDSP
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	9.31		CHEMBL
Voltage-dependent calcium channel gamma-1 subunit	Ion channel	Q06432	CCG1_HUMAN					WOMBAT-PK
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.25		CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	5.62		CHEMBL
Equilibrative nucleoside transporter 4	Transporter	Q7RTT9	S29A4_HUMAN	INHIBITOR	Ki	4.49		IUPHAR
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.26		PDSP
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	9.60		CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		Ki	6.79		CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		Ki	5.19		CHEMBL
Transporter	Transporter		Q9WTR4_RAT		Ki	9.19		CHEMBL
Sodium-dependent noradrenaline transporter	Transporter		SC6A2_MOUSE		IC50	5.80		CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_MOUSE		IC50	5.03		CHEMBL
Histamine H1 receptor	GPCR		HRH1_RAT		IC50	9.10		CHEMBL
Transporter	Transporter		Q63380_RAT		Ki	9.11		CHEMBL
Serotonin (5-HT) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT 5HT2B_RAT 5HT6R_RAT 5HT7R_RAT 5HT5A_RAT 5HT5B_RAT 5HT3A_RAT 5HT4R_RAT 5HT3B_RAT		IC50	6.46		CHEMBL
G protein-activated inward rectifier potassium channel 4	Ion channel		KCNJ5_MOUSE	BLOCKER	IC50	4.30		IUPHAR
G protein-activated inward rectifier potassium channel 2	Ion channel		KCNJ6_MOUSE	BLOCKER	IC50	4.40		IUPHAR

External reference:

ID	Source
4019708	VUID
N0000147800	NUI
D00812	KEGG_DRUG
58-28-6	SECONDARY_CAS_RN
203174	RXNORM
4018608	VANDF
4019708	VANDF
C0011685	UMLSCUI
CHEBI:47781	CHEBI
DSM	PDB_CHEM_ID
CHEMBL72	ChEMBL_ID
DB01151	DRUGBANK_ID
CHEMBL1696	ChEMBL_ID
D003891	MESH_DESCRIPTOR_UI
2995	PUBCHEM_CID
2399	IUPHAR_LIGAND_ID
1500	INN_ID
TG537D343B	UNII
1064	MMSL
4547	MMSL
d00145	MMSL
001503	NDDF
004602	NDDF
26120001	SNOMEDCT_US
33378002	SNOMEDCT_US
372705002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8218	TABLET, FILM COATED	10 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8218	TABLET, FILM COATED	10 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8972	TABLET, FILM COATED	25 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8972	TABLET, FILM COATED	25 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8973	TABLET, FILM COATED	50 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8973	TABLET, FILM COATED	50 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8974	TABLET, FILM COATED	75 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8974	TABLET, FILM COATED	75 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8975	TABLET, FILM COATED	100 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8975	TABLET, FILM COATED	100 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8976	TABLET, FILM COATED	150 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8976	TABLET, FILM COATED	150 mg	ORAL	ANDA	20 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-586	TABLET, FILM COATED	100 mg	ORAL	ANDA	20 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-830	TABLET, FILM COATED	10 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-428	TABLET, FILM COATED	25 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-845	TABLET	10 mg	ORAL	ANDA	15 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-578	TABLET	10 mg	ORAL	ANDA	13 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-579	TABLET	25 mg	ORAL	ANDA	13 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-580	TABLET	50 mg	ORAL	ANDA	13 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-581	TABLET	75 mg	ORAL	ANDA	13 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-582	TABLET	100 mg	ORAL	ANDA	13 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-583	TABLET	150 mg	ORAL	ANDA	13 sections
Desipramine Hydrochloride	Human Prescription Drug Label	1	24724-067	TABLET	10 mg	ORAL	ANDA	17 sections
Desipramine Hydrochloride	Human Prescription Drug Label	1	24724-068	TABLET	25 mg	ORAL	ANDA	17 sections
Desipramine Hydrochloride	Human Prescription Drug Label	1	24724-069	TABLET	50 mg	ORAL	ANDA	17 sections
Desipramine Hydrochloride	Human Prescription Drug Label	1	24724-070	TABLET	75 mg	ORAL	ANDA	17 sections
Desipramine Hydrochloride	Human Prescription Drug Label	1	24724-071	TABLET	100 mg	ORAL	ANDA	17 sections
Desipramine Hydrochloride	Human Prescription Drug Label	1	24724-072	TABLET	150 mg	ORAL	ANDA	17 sections
Norpramin	HUMAN PRESCRIPTION DRUG LABEL	1	30698-007	TABLET, SUGAR COATED	10 mg	ORAL	NDA	21 sections
Norpramin	HUMAN PRESCRIPTION DRUG LABEL	1	30698-011	TABLET, SUGAR COATED	25 mg	ORAL	NDA	21 sections